
In a randomized trial, the efficacy and safety of Moluodan in reversing gastric precancerous lesions were investigated. Over a four-year period, 502 patients received Moluodan, folic acid, or a combination. Moluodan demonstrated effectiveness comparable to folic acid, with high-dose Moluodan showing promising trends. Notably, Moluodan excelled in resolving dysplasia, proving safe for extended use. These findings highlight Moluodan's potential in treating gastric precancerous lesions, particularly dysplasia, warranting further exploration.
Like
Save
Share